Updated:
Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc. is a clinical-stage biotechnology company dedicated to discovering and developing novel small-molecule therapies for ophthalmic...
Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc. is a clinical-stage biotechnology company dedicated to discovering and developing novel small-molecule therapies for ophthalmic diseases. The firm's pipeline includes drug candidates targeting retinal diseases such as retinitis pigmentosa and geographic atrophy. Kiora's lead compound, KIO-101, is a clinical-stage non-steroidal anti-inflammatory for the treatment of ocular inflammation. The firm's investment portfolio is centered on its proprietary research and development programs. Kiora's strategy involves acquiring or in-licensing promising drug candidates and advancing them through preclinical and clinical development. The company collaborates with academic institutions and contract research organizations to conduct its clinical trials. Kiora maintains a lean organizational structure as a publicly traded biotechnology company. The firm's team includes experienced executives and scientists with backgrounds in drug development and ophthalmology. Kiora's headquarters and operations are based in the United States. In recent years, the company has completed clinical trials and reported data for its lead programs. Kiora's structural differentiator is its focus on ophthalmic drug development with a small-molecule platform that targets multiple mechanisms of action. This approach contrasts with larger biotech firms that pursue broader therapeutic areas, allowing Kiora to specialize in high-need ophthalmic indications.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
Who leads research and development at Kiora Pharmaceuticals?
Kiora is led by a management team with expertise in drug development and ophthalmology. The chief medical officer and other scientific leaders oversee clinical trial strategy and regulatory interactions. The board of directors includes individuals with pharmaceutical and financial backgrounds.
What is the primary focus of Kiora's drug pipeline?
Kiora's pipeline focuses on small-molecule therapies for ophthalmic diseases, particularly retinal conditions such as retinitis pigmentosa and geographic atrophy. Their lead candidate KIO-101 targets ocular inflammation.
Is Kiora Pharmaceuticals a publicly traded company or privately held?
Kiora Pharmaceuticals is a publicly traded company. It trades on a US stock exchange. This structure provides access to public capital markets for funding its clinical trials.
How does Kiora acquire its drug candidates?
Kiora typically develops drug candidates in-house or through licensing agreements and acquisitions. The company evaluates pharmaceutical assets that fit its ophthalmic expertise.
What are the key risk factors for Kiora's clinical programs?
As a clinical-stage biotech, Kiora faces risks common to drug development, including trial failures, regulatory delays, and competition from larger firms. The company must secure financing for its ongoing operations.
Does Kiora maintain a family office structure separate from its pharmaceutical operations?
Kiora Pharmaceuticals Inc. operates primarily as a biotech company rather than a traditional family office. The firm's structure may involve a controlling family interest, but its public reporting focuses on pharmaceutical activities.
What geographic markets does Kiora target?
Kiora's clinical trials are primarily conducted in the United States. The company may seek regulatory approval in the US and potentially other markets for its drug candidates.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: